Martine Bagot1*, Youn H. Kim, MD2, Pablo L. Ortiz-Romero3*, Pier Luigi Zinzani, MD, PhD4, Neha Mehta-Shah, MD, MSCI5, Olivier Dereure6*, Marie Beylot-Barry7*, Stéphane Dalle8*, Eric D Jacobsen9, Auris Huen, MD, PharmD10*, Andrea Combalia11*, Maxime Battistella, MD, PhD12*, Alejandro A. Gru, MD13*, Hélène Moins-Teisserenc, MD, PhD14*, Michael S. Khodadoust, MD PhD15, Julien Viotti16*, Christine Paiva16*, Marianna Muller16* and Pierluigi Porcu, MD17
1Department of Dermatology, Hôpital Saint Louis, Université Paris Cité, Inserm U976, Paris, CT, France
2Stanford Cancer Institute, Stanford, CA
3Department of Dermatology, Hospital 12 de Octubre Medical School, University Complutense, Madrid, Spain
4Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy
5Division of Oncology, Washington University School of Medicine, St. Louis, MO
6Department of Dermatology, CHU Montpellier, Université Montpellier I, Montpellier, France
7Department of Dermatology, Centre Hospitalier Universitaire de Bordeaux – Hôpital Saint-André, B, Bordeaux, France
8Department of Dermatology, Hospices Civils de Lyon, Pierre Bénite, Lyon, France
9Dana-Farber Cancer Institute, Boston, MA
10Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX
11Department of Dermatology, Hospital Clinic de Barcelona, Barcelona, Spain
12INSERM U1165, Universite Paris 7, AP-HP Hopital Saint Louis, Paris, FRA
13Department of Pathology, University of Virginia, Charlottesville, VA
14Hematology Laboratory, Hopital Saint-Louis, AP-HP, Université Paris Cité, INSERM U976, Paris, France
15Department of Medicine, Divisions of Oncology and Hematology, Stanford University, Stanford, CA
16INNATE PHARMA, Marseille, France
17Sidney Kimmel Cancer Center at Jefferson Health, Thomas Jefferson University, Philadelphia, PA